None listed
Conditions
Interventions
Procedure/Surgery, Others : This study consists of three sub-studies. The purpose of the first sub-study is to construct a pharmacokinetic model of vancomycin in patients with normal renal function. T
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - 1st group, Development of a pharmacokinetic model for vancomycin in ICU patients with normal renal function or mild decreased renal function. 1. Patients over 20 years of age. 2. Patients who hospitalized in surgical intensive care unit of the Asan medical center. 3. Patients in clinical need for vancomycin administration 4. Patients over 60ml/min of glomerular filtration rate, on preoperative laboratory check. 5. Patients over 40 kg of body weight. 6. Patients who voluntarily agreed to be enrolled to the clinical research, or the case which the protector of the patient agreed to be enrolled to the clinical research, instead of the sedated patient. - 2nd group, Development of a pharmacokinetic model for vancomycin in ICU patients with CRRT 1. Patients over 20 years of age. 2. Patients who hospitalized in surgical intensive care unit of the Asan medical center. 3. Patients in clinical need for vancomycin administration 4. Patients who receiving continuous renal replacement therapy(CRRT). 5. Patients over 40 kg of body weight. 6. Patients who voluntarily agreed to be enrolled to the clinical research, or the case which the protector of the patient agreed to be enrolled to the clinical research, instead of the sedated patient. - 3rd and 4th group, Comparison of vancomycin therapeutic effectiveness between standard administration method versus TCI method, in patients with normal renal function 1. Patients over 20 years of age. 2. Patients who hospitalized in surgical intensive care unit of the Asan medical center. 3. Patients in clinical need for vancomycin administration 4. Patients over 60ml/min of glomerular filtration rate, on preoperative laboratory check. 5. Patients over 40 kg of body weight. 6. Patients who voluntarily agreed to be enrolled to the clinical research, or the case which the protector of the patient agreed to be enrolled to the clinical research, instead of the sedated patient.
Exclusion criteria
Exclusion criteria: - 1st group, Development of a pharmacokinetic model for vancomycin in ICU patients with normal renal function or mild decreased renal function. 1. Pregnant female, or female who breast-feeds her baby. 2. Patients who has history of hypersensitivity to the vancomycin. 3. Patients who has history of prior vancomycin administration, within 7 days of the clinical research enroll agreement. 4. Patients below 8 g/dl of hemoglobin concentration. 5. Patients below 60ml/min of glomerular filtration rate, on preoperative laboratory check. 6. Other in-appropriative patients under the researcher's decision. - 2nd group, Development of a pharmacokinetic model for vancomycin in ICU patients with CRRT 1. Pregnant female, or female who breast-feeds her baby. 2. Patients who has history of hypersensitivity to the vancomycin. 3. Patients who has history of prior vancomycin administration, within 7 days of the clinical research enroll agreement. 4. Patients below 8 g/dl of hemoglobin concentration. 5. Other in-appropriative patients under the researcher's decision. - 3rd and 4th group, Comparison of vancomycin therapeutic effectiveness between standard administration method versus TCI method, in patients with normal renal function 1. Pregnant female, or female who breast-feeds her baby. 2. Patients who has history of hypersensitivity to the vancomycin. 3. Patients who has history of prior vancomycin administration, within 7 days of the clinical research enroll agreement. 4. Patients below 8 g/dl of hemoglobin concentration. 5. Patients below 60ml/min of glomerular filtration rate, on preoperative laboratory check. 6. Other in-appropriative patients under the researcher's decision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of acute kidney injury;The volume of distribution and clearance of the vancomycin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive performance of the pharmacokinetic model. | — |
Countries
Korea, Republic of
Contacts
Public ContactByungmoon Choi
Asan Medical Center
Outcome results
None listed